By Josh White
Date: Friday 25 Nov 2022
LONDON (ShareCast) - (Sharecast News) - Omega Diagnostics confirmed the receipt of deferred consideration from the sale of the CD4 business on Friday.
The AIM-traded medical diagnostics company said it had now received the £4m of deferred consideration.
"Accordingly, as of close-of-business on 24 November, Omega held cash balances of £6.5m," the board said in its short statement.
At 1116 GMT, shares in Omega Diagnostics Group were up 10.83% at 3.99p.
Reporting by Josh White for Sharecast.com.
Email this article to a friend
or share it with one of these popular networks:
| Currency | UK Pounds |
| Share Price | 1.95p |
| Change Today | 0.000p |
| % Change | 0.00 % |
| 52 Week High | 3.85 |
| 52 Week Low | 1.80 |
| Volume | 224,335 |
| Shares Issued | 237.95m |
| Market Cap | £4.64m |
| Beta | 0.00 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| No dividends found |
| Time | Volume / Share Price |
| 16:38 | 75,000 @ 1.82p |
| 16:01 | 6,116 @ 1.92p |
| 15:15 | 2,787 @ 1.86p |
| 14:12 | 2,000 @ 1.86p |
| 12:59 | 228 @ 2.20p |
You are here: research